We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PCE +6.6%, Another 40-Year High; XOM, CL, BMY Report
Read MoreHide Full Article
Friday, April 29, 2022
New Personal Consumption Expenditure (PCE) index data for the month of March has hit the tape. It’s one of the prime inflation prints informing Fed decisions on monetary policy — the next of which comes just next week. Headline PCE last month came in at +1.4%, ahead of the +0.6% initially reported for February.
Year over year PCE managed to hit a 40-year high: +6.6%, above the originally reported +6.4% for February. Stripping out volatile food and energy products, the “core” read on March PCE came in at +5.2% — a tad lower than the +5.3% expected and the +5.4% initially reported the previous month. This illustrates that inflation was clear and present in March, but a large chunk of it was due to food and energy prices.
Real Personal Spending reached +0.2%, swinging to a positive from -0.1% expected and -0.4% in February. As we saw in the initial read on Q1 GDP earlier this week, the consumer appears to be doing his/her part in keeping the economy strong. Clearly, ratcheting down energy costs — which subsequently affect food costs due to deliveries, etc. — would go a long way toward staunching inflation. A 50 basis-point interest rate hike next week from the Fed will also play a part in this.
Exxon Mobil (XOM - Free Report) missed estimates on its Q1 earnings this morning, with $2.07 per share coming up short of the $2.25 expected in the Zacks consensus. Much of this has to do with a -$3.4 billion write-off in doing its part to boycott Russian oil. Revenues in the quarter beat estimates by +1.8% to $90.5 billion, and is miles ahead of the year-ago $59.15 billion in revenues. Shares are flat on the news; the stock is +42% year to date. For more on XOM’s earnings, click here.
Colgate-Palmolive (CL - Free Report) posted only its second earnings miss in the past five years — though three of the previous four quarters just came in-line with expectations — with 74 cents per share shy of the 80 cents anticipated. Sales in the quarter of $4.4 billion were slightly shy of expectations, but slightly above the year-ago tally. Shares are down -5% on the miss, adding to the -5% year to date for the Consumer Staples giant. For more on CL’s earnings, click here.
Bristol Myers-Squibb (BMY - Free Report) took out estimates on both top and bottom lines for the third time in the past four quarters: earnings of $1.92 per share easily surpassed the $1.74 expected, on $11.65 billion in revenues, which topped estimates by +3.5%. However, reduced earnings estimates for the Big Pharma company for the full year are taking down shares -5% ahead of the opening bell. For more on BMY’s earnings, click here.
Image: Bigstock
PCE +6.6%, Another 40-Year High; XOM, CL, BMY Report
Friday, April 29, 2022
New Personal Consumption Expenditure (PCE) index data for the month of March has hit the tape. It’s one of the prime inflation prints informing Fed decisions on monetary policy — the next of which comes just next week. Headline PCE last month came in at +1.4%, ahead of the +0.6% initially reported for February.
Year over year PCE managed to hit a 40-year high: +6.6%, above the originally reported +6.4% for February. Stripping out volatile food and energy products, the “core” read on March PCE came in at +5.2% — a tad lower than the +5.3% expected and the +5.4% initially reported the previous month. This illustrates that inflation was clear and present in March, but a large chunk of it was due to food and energy prices.
Real Personal Spending reached +0.2%, swinging to a positive from -0.1% expected and -0.4% in February. As we saw in the initial read on Q1 GDP earlier this week, the consumer appears to be doing his/her part in keeping the economy strong. Clearly, ratcheting down energy costs — which subsequently affect food costs due to deliveries, etc. — would go a long way toward staunching inflation. A 50 basis-point interest rate hike next week from the Fed will also play a part in this.
Exxon Mobil (XOM - Free Report) missed estimates on its Q1 earnings this morning, with $2.07 per share coming up short of the $2.25 expected in the Zacks consensus. Much of this has to do with a -$3.4 billion write-off in doing its part to boycott Russian oil. Revenues in the quarter beat estimates by +1.8% to $90.5 billion, and is miles ahead of the year-ago $59.15 billion in revenues. Shares are flat on the news; the stock is +42% year to date. For more on XOM’s earnings, click here.
Colgate-Palmolive (CL - Free Report) posted only its second earnings miss in the past five years — though three of the previous four quarters just came in-line with expectations — with 74 cents per share shy of the 80 cents anticipated. Sales in the quarter of $4.4 billion were slightly shy of expectations, but slightly above the year-ago tally. Shares are down -5% on the miss, adding to the -5% year to date for the Consumer Staples giant. For more on CL’s earnings, click here.
Bristol Myers-Squibb (BMY - Free Report) took out estimates on both top and bottom lines for the third time in the past four quarters: earnings of $1.92 per share easily surpassed the $1.74 expected, on $11.65 billion in revenues, which topped estimates by +3.5%. However, reduced earnings estimates for the Big Pharma company for the full year are taking down shares -5% ahead of the opening bell. For more on BMY’s earnings, click here.
Questions or comments about this article and/or its author? Click here>>